Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07597070 | Universal Immunization to Fortify Immunotherapy Efficacy and Response(UNIFIER) | not yet recruiting | Phase 2 | 500 | University of FloridaOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07845786 | Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)(STELLAR-202) | not yet recruiting | Phase 2 | 60 | ExelixisINDUSTRY | 0 | Sep 29, 2026 |
| clinicaltrials |
| NCT07845916 | Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer(QS-NSCLC) | not yet recruiting | Phase 2 | 12 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07846358 | This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.(GFH276X1203) | not yet recruiting | Phase 1 / Phase 2 | 84 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07842471 | Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC | not yet recruiting | Phase 2 | 117 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07836543 | Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer | not yet recruiting | Phase 2 | 105 | Ming ChenOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT05745740 | A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation | not yet recruiting | Phase 1 / Phase 2 | 26 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07827261 | A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 36 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07824882 | A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations | not yet recruiting | Phase 2 | 76 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Sep 17, 2026 | clinicaltrials |
| NCT07806773 | Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 80 | Tubulis GmbHINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07822984 | Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy | not yet recruiting | Phase 2 | 374 | Fudan UniversityOTHER | 0 | Sep 16, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819578 | Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC | not yet recruiting | Phase 2 | 30 | Shaodong HongOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07818304 | SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC(Endouble 2) | not yet recruiting | Phase 2 | 61 | The First People's Hospital of LianyungangOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07807722 | Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC | not yet recruiting | Phase 2 | 29 | Hubei Cancer HospitalOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07808138 | RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer(RADICAL-IO) | not yet recruiting | Phase 2 | 30 | The Netherlands Cancer InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07802834 | Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC | not yet recruiting | Phase 2 | 42 | Stanford UniversityOTHER | 0 | Sep 3, 2026 | clinicaltrials |
| NCT07543172 | CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer | not yet recruiting | Phase 2 | 29 | Roswell Park Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07355231 | Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI(GuidedRT) | not yet recruiting | Phase 1 / Phase 2 | 10 | Xemed LLCINDUSTRY | 0 | Sep 1, 2026 | clinicaltrials |
| NCT07796438 | Low-Frequency rTMS for In-Hospital Sleep Disturbance in Advanced NSCLC | not yet recruiting | Phase 2 | 160 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Sep 1, 2026 | clinicaltrials |
| NCT07789444 | Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EGFR+ NSCLC With Brain Mets | not yet recruiting | Phase 2 | 53 | Xiaorong DongOTHER | 0 | Aug 27, 2026 | clinicaltrials |
| NCT07551778 | Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 42 | BOE Technology Group Co., Ltd.INDUSTRY | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07739186 | A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) | not yet recruiting | Phase 2 / Phase 3 | 120 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07780578 | The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 34 | Fudan UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07770100 | Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) | not yet recruiting | Phase 2 | 35 | Mark BernardOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07775040 | Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial | not yet recruiting | Phase 2 | 43 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07777614 | OPTIMISE Lung SABR | not yet recruiting | Phase 2 | 208 | Cancer Trials IrelandNETWORK | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07771764 | A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 30 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07432984 | Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC(FMT-LUNG) | not yet recruiting | Phase 2 | 15 | Se-Hoon LeeOTHER | 0 | Aug 11, 2026 | clinicaltrials |
| NCT07718737 | Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy | not yet recruiting | Phase 2 / Phase 3 | 512 | Multitude Therapeutics Inc.INDUSTRY | 2 | Aug 10, 2026 | clinicaltrials |
| NCT07746388 | Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial | not yet recruiting | Phase 2 | 30 | University of Maryland, BaltimoreOTHER | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07750704 | Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC | not yet recruiting | Phase 2 | 153 | Guangdong Association of Clinical TrialsOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07741344 | Study of Robotic Assisted/Image Guided Electromagnetic Navigation Bronchoscopic Therapies and Surgery in Stage IA NSCLC | not yet recruiting | Phase 2 | 292 | Chinese University of Hong KongOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07742956 | Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants. | not yet recruiting | Phase 2 | 156 | Shanghai Allink Biotherapeutics Co., Ltd.INDUSTRY | 0 | Aug 3, 2026 | clinicaltrials |
| NCT07739966 | A Study of DS-3939a in Participants With Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 400 | Daiichi SankyoINDUSTRY | 0 | Jul 31, 2026 | clinicaltrials |
| NCT07720167 | Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 38 | Medical University of South CarolinaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07709585 | Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients(BE-MASTER) | not yet recruiting | Phase 2 | 124 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07653438 | In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy(PulmoPrint) | not yet recruiting | Phase 2 | 20 | University Medical Center GroningenOTHER | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07704645 | The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 180 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07688577 | XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 140 | Xilio Development, Inc.INDUSTRY | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07685197 | Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC | not yet recruiting | Phase 2 | 100 | Zhou ChengzhiOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07662811 | SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 396 | Shanghai Chest HospitalOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07670715 | Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07661173 | A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 154 | Anhui Provincial Cancer HospitalOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07358689 | Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 120 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07146230 | The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2(SPRINT 2) | not yet recruiting | Phase 2 | 52 | Montefiore Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | not yet recruiting | Phase 2 | 15 | Haihua YuanOTHER | 0 | Jun 8, 2026 | clinicaltrials |
Data updated 19 hours agoSource updated Sep 29, 2026source: clinicaltrials